MXPA04003606A - Inhibidores de factor xa y de otras proteasas de serina implicadas en la caida en la cascada de la coagulacion. - Google Patents

Inhibidores de factor xa y de otras proteasas de serina implicadas en la caida en la cascada de la coagulacion.

Info

Publication number
MXPA04003606A
MXPA04003606A MXPA04003606A MXPA04003606A MXPA04003606A MX PA04003606 A MXPA04003606 A MX PA04003606A MX PA04003606 A MXPA04003606 A MX PA04003606A MX PA04003606 A MXPA04003606 A MX PA04003606A MX PA04003606 A MXPA04003606 A MX PA04003606A
Authority
MX
Mexico
Prior art keywords
inhibitors
factor
serine proteases
coagulation cascade
formula
Prior art date
Application number
MXPA04003606A
Other languages
English (en)
Inventor
Thomas Kohrt Jeffrey
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA04003606A publication Critical patent/MXPA04003606A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invencion proporciona compuestos de Formula (I):En la que A, B, C, G, y W1 tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmaceuticamente aceptables de los mismos, que son utiles para tratar trastornos tromboticos. Tambien se describen composiciones farmaceuticas que comprenden uno o mas compuestos de Formula I, procedimientos para la preparacion de compuestos de Formula I e intermedios utiles para la preparacion de compuestos de Formula I.
MXPA04003606A 2001-11-29 2002-11-14 Inhibidores de factor xa y de otras proteasas de serina implicadas en la caida en la cascada de la coagulacion. MXPA04003606A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33416801P 2001-11-29 2001-11-29
US38489502P 2002-05-31 2002-05-31
PCT/IB2002/004757 WO2003045912A1 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade

Publications (1)

Publication Number Publication Date
MXPA04003606A true MXPA04003606A (es) 2004-07-27

Family

ID=26989068

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003606A MXPA04003606A (es) 2001-11-29 2002-11-14 Inhibidores de factor xa y de otras proteasas de serina implicadas en la caida en la cascada de la coagulacion.

Country Status (42)

Country Link
US (6) US7030141B2 (es)
EP (3) EP2085391A3 (es)
JP (1) JP4238135B2 (es)
KR (2) KR100688814B1 (es)
CN (1) CN1582274B (es)
AP (1) AP1744A (es)
AR (1) AR037676A1 (es)
AT (2) ATE320414T1 (es)
AU (1) AU2002365313B2 (es)
BR (1) BR0214519A (es)
CA (1) CA2468715C (es)
CR (2) CR7332A (es)
CY (2) CY1105374T1 (es)
DE (2) DE60209944T2 (es)
DK (2) DK1465864T3 (es)
DO (1) DOP2002000525A (es)
EA (1) EA007579B1 (es)
EC (1) ECSP045126A (es)
ES (2) ES2308653T3 (es)
GE (1) GEP20063871B (es)
GT (2) GT200200248A (es)
HR (1) HRP20040470A2 (es)
HU (1) HUP0402529A3 (es)
IL (1) IL161826A0 (es)
IS (1) IS2552B (es)
MA (1) MA27146A1 (es)
MX (1) MXPA04003606A (es)
MY (1) MY132419A (es)
NO (1) NO327006B1 (es)
NZ (1) NZ532384A (es)
OA (1) OA13064A (es)
PA (1) PA8559101A1 (es)
PE (1) PE20030662A1 (es)
PL (1) PL370134A1 (es)
PT (2) PT1465864E (es)
RS (1) RS51087B (es)
SI (2) SI1465864T1 (es)
SV (1) SV2004001414A (es)
TN (1) TNSN04098A1 (es)
TW (1) TWI324515B (es)
UY (1) UY27558A1 (es)
WO (1) WO2003045912A1 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
DE10113379B4 (de) * 2001-03-20 2006-08-24 Karl Eugen Fischer Gmbh Maschinenfabrik Vorschubeinrichtung, insbesondere für Cordbänder
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
KR20030080810A (ko) * 2002-04-11 2003-10-17 주식회사 엘지생명과학 아미노피리도아릴 그룹을 가진 선택적 트롬빈 억제제
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
EP1720844B1 (de) * 2003-04-03 2009-04-29 MERCK PATENT GmbH Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
DE10329457A1 (de) * 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate
MXPA05013536A (es) * 2003-06-18 2006-03-09 Merck Patent Gmbh Derivados de etinilprolina.
EP1670739A4 (en) 2003-10-08 2007-08-08 Bristol Myers Squibb Co CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
DE10358814A1 (de) * 2003-12-16 2005-07-21 Merck Patent Gmbh Prolinylarylacetamide
WO2005085200A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. ピリドン誘導体
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
DE102004016605A1 (de) * 2004-04-03 2005-10-20 Merck Patent Gmbh Thiocarbamoylproline
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008504280A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004047254A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
DE102004047255A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Prolinderivate
WO2006038119A1 (en) * 2004-10-08 2006-04-13 Warner-Lambert Company Llc Stereoselective synthesis of n-protected alkoxy prolines
BRPI0517964A (pt) * 2004-11-03 2008-10-28 Hoffmann La Roche derivados de dicarboxamida
CA2587678C (en) * 2004-11-16 2013-05-21 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
AU2006226043A1 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Crystalline forms of a known pyrrolidine factor Xa inhibitor
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
KR20080023680A (ko) 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
AU2006271781A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
WO2007053610A2 (en) * 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP1951717A1 (en) 2005-11-16 2008-08-06 F.Hoffmann-La Roche Ag Novel pyrrolidine derivatives as inhibitors of coagulation factor xa
RU2008128452A (ru) * 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP1847537A1 (en) * 2006-04-21 2007-10-24 F. Hoffmann-La Roche Ag Dicarboxamide derivatives
EA200802210A1 (ru) * 2006-05-16 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
WO2008044700A1 (fr) * 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
JP2010510246A (ja) * 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
JP2010511034A (ja) * 2006-11-29 2010-04-08 ファイザー・プロダクツ・インク 第Ｘａ因子阻害剤としての（Ｒ）−５−メチル−４，５−ジヒドロ−ピラゾール−１，５−ジカルボン酸１−［（４−クロロ−フェニル）−アミド］５−｛［２−フルオロ−４−（２−オキソ−２Ｈ−ピリジン−１−イル）−フェニル］−アミド｝
WO2008075172A2 (en) 2006-12-19 2008-06-26 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
KR101473207B1 (ko) 2007-04-13 2014-12-16 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
DK2227466T3 (da) * 2007-11-30 2011-08-08 Bayer Schering Pharma Ag Heteroaryl-substituerede piperidiner
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
KR20110028661A (ko) * 2008-07-15 2011-03-21 노파르티스 아게 Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
JP2013503909A (ja) * 2009-09-04 2013-02-04 ヴァンダービルト ユニバーシティー ｍＧＬｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
PE20140471A1 (es) 2011-01-04 2014-04-13 Novartis Ag Moduladores de la via del complemento y usos de los mismos
WO2013102242A1 (en) 2012-01-06 2013-07-11 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
US10730862B2 (en) * 2012-01-12 2020-08-04 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
ES2648962T3 (es) 2012-06-28 2018-01-09 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la vía del complemento
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867226B1 (en) 2012-06-28 2018-11-14 Novartis AG Complement pathway modulators and uses thereof
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
EA201590200A1 (ru) 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
CN103570630B (zh) 2012-07-18 2016-04-20 广东东阳光药业有限公司 氮杂环衍生物及其在药物中的应用
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EA201300843A1 (ru) * 2013-08-01 2015-04-30 Арсений Валерьевич Айбушев Карбамоилфенильные производные для остановки, предотвращения и профилактики кровотечений или усиления системы гемостаза
CN103570699A (zh) * 2013-09-29 2014-02-12 北京万全德众医药生物技术有限公司 一种制备普卡必利的方法
AU2015226855C1 (en) 2014-03-07 2021-02-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102616762B1 (ko) 2015-03-18 2023-12-20 아비나스 오퍼레이션스, 인코포레이티드 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
DK4019022T3 (en) * 2015-10-01 2024-02-19 Biocryst Pharm Inc Human plasma kallikrein inhibitors
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3209295A1 (en) 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
CN111132673A (zh) 2017-05-03 2020-05-08 维瓦斯治疗公司 非稠合三环化合物
JP7245229B2 (ja) 2017-08-21 2023-03-23 ビバーチェ セラピューティクス，インク． ベンゾスルホニル化合物
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
CA3084648A1 (en) * 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
CN110240591A (zh) * 2018-03-08 2019-09-17 天津药物研究院有限公司 脯氨酸衍生物及其制备方法和用途
WO2019185868A1 (en) * 2018-03-29 2019-10-03 Centre National De La Recherche Scientifique P2rx7 modulators in therapy
CA3095494C (en) 2018-04-04 2023-11-07 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
JP2023507570A (ja) 2019-12-19 2023-02-24 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体の標的分解のための化合物および方法
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91116A (en) * 1869-06-08 Improvement in guard for door-knobs
US2947755A (en) * 1959-02-05 1960-08-02 Wallace & Tiernan Inc Substituted 1-m-aminophenyl-2-pyridones
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5118691A (en) * 1990-09-20 1992-06-02 Warner-Lambert Co. Substituted tetrahydropyridines as central nervous system agents
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5681844A (en) * 1994-04-18 1997-10-28 Corvas International, Inc. Methionine sulfone and s-substituted cysteine sulfone derivatives as enzyme inhibitors
GB9515489D0 (en) 1995-07-28 1995-09-27 Sandoz Ltd Organic compounds
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HU224315B1 (hu) 1996-06-05 2005-07-28 Gyógyszerkutató Intézet Kft. Véralvadásgátló hatású peptidil-arginin-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
CA2288330C (en) 1997-05-07 2014-02-11 University Of Pittsburgh Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases
JP4344960B2 (ja) * 1997-05-23 2009-10-14 バイエル、コーポレイション アリール尿素によるｐ３８キナーゼ活性の阻害
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
RU2002110295A (ru) 1999-09-17 2003-12-10 Милленниум Фармасьютикалс, Инк. (Us) Ингибиторы фактора Ха
DE10008329A1 (de) 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
ATE311366T1 (de) * 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
DE60120661T2 (de) * 2000-03-27 2007-07-05 Applied Research Systems Ars Holding N.V. Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren
DK1268419T3 (da) * 2000-03-27 2006-10-02 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
DE10036121A1 (de) 2000-07-25 2002-02-07 Merck Patent Gmbh N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate
DE10046272A1 (de) 2000-09-19 2002-03-28 Merck Patent Gmbh Aminoheterocyclen (Faktor Xa Inhibitoren 14)
DE10050723A1 (de) 2000-10-13 2002-04-25 Merck Patent Gmbh N-Substituierte Aminosäurederivate (Faktor Xa Inhibitoren 12)
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10102322A1 (de) 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
FR2864958B1 (fr) * 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
DE102005038537A1 (de) * 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
WO2008062739A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
DE102007037017A1 (de) * 2007-08-06 2009-02-19 Clariant International Ltd. 1-Alkyl-5-oxo-pyrrolidin-3-carbonsäureester mit verbesserter biologischer Abbaubarkeit

Also Published As

Publication number Publication date
ATE320414T1 (de) 2006-04-15
US20080287674A1 (en) 2008-11-20
PA8559101A1 (es) 2003-11-12
EP1465864B1 (en) 2006-03-15
US7030141B2 (en) 2006-04-18
DE60209944T2 (de) 2006-11-23
US7407972B2 (en) 2008-08-05
AP1744A (en) 2007-05-29
CR10190A (es) 2008-09-10
DK1465864T3 (da) 2006-07-10
HRP20040470A2 (en) 2004-10-31
US20050267118A1 (en) 2005-12-01
GEP20063871B (en) 2006-07-10
US20090221546A1 (en) 2009-09-03
TNSN04098A1 (fr) 2006-06-01
CA2468715C (en) 2011-03-29
US20050250815A1 (en) 2005-11-10
IS2552B (is) 2009-10-15
PE20030662A1 (es) 2003-08-11
EA007579B1 (ru) 2006-12-29
CA2468715A1 (en) 2003-06-05
EP2085391A2 (en) 2009-08-05
RS51087B (sr) 2010-10-31
GT200200248AA (es) 2007-07-06
ES2259113T3 (es) 2006-09-16
EP2085391A3 (en) 2010-08-18
NO20042270L (no) 2004-06-01
CY1105374T1 (el) 2010-04-28
EP1671949A3 (en) 2006-07-19
IL161826A0 (en) 2005-11-20
ES2308653T3 (es) 2008-12-01
KR100688814B1 (ko) 2007-03-02
HUP0402529A2 (hu) 2005-03-29
AU2002365313A1 (en) 2003-06-10
KR20060100481A (ko) 2006-09-20
DK1671949T3 (da) 2008-11-03
BR0214519A (pt) 2004-10-13
TWI324515B (en) 2010-05-11
EP1671949A2 (en) 2006-06-21
ATE402148T1 (de) 2008-08-15
GT200200248A (es) 2003-06-27
US7407974B2 (en) 2008-08-05
AP2004003035A0 (en) 2004-06-30
EP1671949B1 (en) 2008-07-23
CR7332A (es) 2006-08-09
KR100712782B1 (ko) 2007-05-02
DE60227853D1 (de) 2008-09-04
PL370134A1 (en) 2005-05-16
CN1582274B (zh) 2011-03-09
SI1671949T1 (sl) 2008-10-31
EP1465864A1 (en) 2004-10-13
RS43604A (en) 2006-12-15
DE60209944D1 (de) 2006-05-11
NO327006B1 (no) 2009-04-06
CN1582274A (zh) 2005-02-16
PT1671949E (pt) 2008-09-17
IS7220A (is) 2004-04-15
UY27558A1 (es) 2003-06-30
TW200300675A (en) 2003-06-16
DOP2002000525A (es) 2003-05-31
ECSP045126A (es) 2004-07-23
JP2005515985A (ja) 2005-06-02
EA200400606A1 (ru) 2004-10-28
SV2004001414A (es) 2004-05-07
WO2003045912A8 (en) 2003-10-02
JP4238135B2 (ja) 2009-03-11
CY1109068T1 (el) 2014-07-02
MA27146A1 (fr) 2005-01-03
MY132419A (en) 2007-10-31
US20060264626A1 (en) 2006-11-23
US20030162787A1 (en) 2003-08-28
OA13064A (en) 2006-11-10
NZ532384A (en) 2006-10-27
PT1465864E (pt) 2006-06-30
KR20040066851A (ko) 2004-07-27
AR037676A1 (es) 2004-12-01
WO2003045912A1 (en) 2003-06-05
SI1465864T1 (sl) 2006-08-31
HUP0402529A3 (en) 2011-05-30
AU2002365313B2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
AP1744A (en) Inhibitors of factor XA and other serine proteases involved in the coagulation cascade
WO2005099709A3 (en) Bicyclic heterocycles useful as serine protease inhibitors
WO2004094372A3 (en) Compounds useful as serine protease inhibitors
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
MXPA06014799A (es) Heterociclos de seis miembros utiles como inhibidores de serina proteasa.
WO2004080971A8 (en) Tetrahydroquinoline derivatives useful as serine protease inhibitors
MXPA03010724A (es) Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
WO2003065987A3 (en) Granzyme b inhibitors
AP2002002616A0 (en) Antidibetic agents
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
WO2005056535A8 (en) 1,2,3-triazole amide derivatives as inhibitors of cytokine production
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
WO2002080853A3 (en) Fused heterocyclic inhibitors of factor xa
ATE443044T1 (de) Tace inhibitoren
RS33304A (en) Phosphonic and compounds as inhibitors of serine proteases
MXPA04005151A (es) Compuestos terapeuticos.
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
WO2002094197A3 (en) Bicyclic inhibitors of factor xa
UY27311A1 (es) Agentes antibacterianos
DE60312154D1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
WO2002006190A3 (en) Crystalline and salt forms of an hiv protease inhibitor
AU2002254907A1 (en) Diamides which inhibit tryptase and factor xa activity
TW200612952A (en) Six-membered heterocycles useful as serine protease inhibitors
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors

Legal Events

Date Code Title Description
FG Grant or registration